Developer docs
API playgroundTry for free, no card

Search company profiles

Forest Laboratories

Full company profile

uuid0025yir

Namestring
Forest Laboratories
Legal namestring
Forest Laboratories, LLC
Websiteurl
frx.com
Company typeenum
Private
Founded yearint
1954
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmaceutical manufacturing, branded prescription drugs, CNS therapeutics, learning disability treatments, specialty pharmaceuticals
Industry2 codes
1Neurology & Psychiatry (CNS) Pharmaceuticals
CodeHLAIAAAFPrimaryYes
2Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
Social media profiles1 record
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Forest Laboratories fundamentally developed, manufactured, and marketed branded pharmaceutical products, with historical emphasis on treatments for central nervous system (CNS) conditions and learning disabilities. Its commercial activities centered on prescription medications marketed to healthcare providers and patients, supported by an acquisition-driven growth strategy that expanded its therapeutic portfolio across multiple disease areas.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Learning Disabilities Treatment Pharmaceuticals
CategorySpecialty Pharmaceuticals / CNS Therapeutics
Description

Branded pharmaceutical products developed and marketed for the treatment of learning disabilities and related CNS conditions, targeted to healthcare providers and patients.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Pfizer
TypeBroad incumbent
Description

Pfizer is a large branded innovator pharmaceutical company with historic CNS and neurology exposure (e.g., legacy neuropathic pain, CNS franchises). Comparable as a broad-incumbent pharma with adjacent CNS therapeutic reach and similar scale dynamics.

2AbbVie
TypeBroad incumbent
Description

AbbVie is the current ultimate parent of Forest Laboratories following the 2020 acquisition of Allergan. AbbVie's $63 billion Allergan deal absorbed Forest and now controls its CNS franchise as part of a portfolio spanning 30+ brands and 60+ therapeutic conditions.

3Jazz Pharmaceuticals
TypeDirect peer
Description

Jazz Pharmaceuticals is a specialty pharma company with material CNS exposure (e.g., neuroscience franchise for narcolepsy, epilepsy, and other CNS disorders). Comparable as a focused specialty pharma peer competing in CNS-adjacent therapeutic areas.

4Allergan (legacy)
TypeBroad incumbent
Description

Allergan acquired Forest Laboratories in 2014 for approximately $25 billion and operated it as a subsidiary until AbbVie's 2020 acquisition. Allergan's diversified specialty pharma portfolio offered overlapping CNS and broader therapeutic capabilities during its ownership of Forest.

5GlaxoSmithKline
TypeBroad incumbent
Description

GSK is a large branded pharmaceutical company with CNS and neurology product lines. Comparable as a broad-incumbent pharma with branded small-molecule drug development, commercialization, and regulatory expertise across overlapping therapeutic categories.

6Lundbeck
TypeDirect peer
Description

Lundbeck is a specialty pharmaceutical company focused exclusively on CNS and brain diseases — its portfolio includes treatments for depression, anxiety, Alzheimer's, Parkinson's, and other neurological disorders that overlap directly with Forest's CNS specialty focus.

7CogniFit
TypeEmerging player
Description

CogniFit is explicitly named as a key industry player alongside Forest Laboratories in the global Learning Disabilities Treatment market. As an emerging player, CogniFit addresses learning disabilities through cognitive training software rather than pharmaceuticals, offering an adjacent rather than directly competing modality.

8Eli Lilly and Company
TypeDirect peer
Description

Eli Lilly is explicitly named as a key competitor alongside Forest Laboratories in the global Learning Disabilities Treatment market. Both companies operate in branded CNS pharmaceuticals with overlapping therapeutic areas including neurology and psychiatry.

9Takeda Pharmaceutical Company
TypeDirect peer
Description

Takeda is explicitly named as a key competitor of Forest Laboratories in the global Learning Disabilities Treatment market. Both companies participate in branded CNS pharmaceutical development with comparable target patient populations and regulatory pathways.

10Novartis
TypeBroad incumbent
Description

Novartis is a large branded innovator pharmaceutical company with neurology and CNS therapeutic areas (e.g., multiple sclerosis, neurology). Comparable as a broad-incumbent pharma with overlapping R&D and commercialization capabilities in CNS-adjacent indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Forest Laboratories

Pharmaceuticalsfrx.com

Forest Laboratories firmographics

Firmographics
Name
Forest Laboratories
Legal name
Forest Laboratories, LLC
Website
https://frx.com
Company type
Private
Founded year
1954
Operating status
Acquired
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Forest Laboratories industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
akta.pro secondary industry
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

  • Pharmaceutical manufacturing
  • Branded prescription drugs
  • CNS therapeutics
  • Learning disability treatments
  • Specialty pharmaceuticals

Where Forest Laboratories is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Forest Laboratories business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Forest Laboratories product offering

Product offering

Core offering

Forest Laboratories fundamentally developed, manufactured, and marketed branded pharmaceutical products, with historical emphasis on treatments for central nervous system (CNS) conditions and learning disabilities. Its commercial activities centered on prescription medications marketed to healthcare providers and patients, supported by an acquisition-driven growth strategy that expanded its therapeutic portfolio across multiple disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Learning Disabilities Treatment Pharmaceuticals Branded pharmaceutical products developed and marketed for the treatment of learning disabilities and related CNS conditions, targeted to healthcare providers and patients.

Companies that use Forest Laboratories

Customer profile

Segments1 record

Ideal customer profiles1 record

Forest Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Forest Laboratories partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Forest Laboratories competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Pfizer is a large branded innovator pharmaceutical company with historic CNS and neurology exposure (e.g., legacy neuropathic pain, CNS franchises). Comparable as a broad-incumbent pharma with adjacent CNS therapeutic reach and similar scale dynamics.
  • AbbVie: AbbVie is the current ultimate parent of Forest Laboratories following the 2020 acquisition of Allergan. AbbVie's $63 billion Allergan deal absorbed Forest and now controls its CNS franchise as part of a portfolio spanning 30+ brands and 60+ therapeutic conditions.
  • Allergan (legacy): Allergan acquired Forest Laboratories in 2014 for approximately $25 billion and operated it as a subsidiary until AbbVie's 2020 acquisition. Allergan's diversified specialty pharma portfolio offered overlapping CNS and broader therapeutic capabilities during its ownership of Forest.
  • GlaxoSmithKline: GSK is a large branded pharmaceutical company with CNS and neurology product lines. Comparable as a broad-incumbent pharma with branded small-molecule drug development, commercialization, and regulatory expertise across overlapping therapeutic categories.
  • Novartis: Novartis is a large branded innovator pharmaceutical company with neurology and CNS therapeutic areas (e.g., multiple sclerosis, neurology). Comparable as a broad-incumbent pharma with overlapping R&D and commercialization capabilities in CNS-adjacent indications.

Direct peers

  • Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharma company with material CNS exposure (e.g., neuroscience franchise for narcolepsy, epilepsy, and other CNS disorders). Comparable as a focused specialty pharma peer competing in CNS-adjacent therapeutic areas.
  • Lundbeck: Lundbeck is a specialty pharmaceutical company focused exclusively on CNS and brain diseases — its portfolio includes treatments for depression, anxiety, Alzheimer's, Parkinson's, and other neurological disorders that overlap directly with Forest's CNS specialty focus.
  • Eli Lilly and Company: Eli Lilly is explicitly named as a key competitor alongside Forest Laboratories in the global Learning Disabilities Treatment market. Both companies operate in branded CNS pharmaceuticals with overlapping therapeutic areas including neurology and psychiatry.
  • Takeda Pharmaceutical Company: Takeda is explicitly named as a key competitor of Forest Laboratories in the global Learning Disabilities Treatment market. Both companies participate in branded CNS pharmaceutical development with comparable target patient populations and regulatory pathways.

Emerging players

  • CogniFit: CogniFit is explicitly named as a key industry player alongside Forest Laboratories in the global Learning Disabilities Treatment market. As an emerging player, CogniFit addresses learning disabilities through cognitive training software rather than pharmaceuticals, offering an adjacent rather than directly competing modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Forest Laboratories social profiles

Digital presence

Forest Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Forest Laboratories leadership team

Management profile

Number of profiles

Forest Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Forest Laboratories M&A and investment

M&A and investment

M&A4 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Forest Laboratories

What does Forest Laboratories do?

Forest Laboratories fundamentally developed, manufactured, and marketed branded pharmaceutical products, with historical emphasis on treatments for central nervous system (CNS) conditions and learning disabilities. Its commercial activities centered on prescription medications marketed to healthcare providers and patients, supported by an acquisition-driven growth strategy that expanded its therapeutic portfolio across multiple disease areas.

Is Forest Laboratories a public or private company?

Forest Laboratories is a private company. It is classified as corporate owned and is currently acquired.

When was Forest Laboratories founded?

Forest Laboratories was founded in 1954. It employs 1,001 to 5,000 people.

Where is Forest Laboratories based?

Forest Laboratories is headquartered in New York, United States, in the North America region.

Who are Forest Laboratories's main competitors?

Broad incumbents on record are Pfizer, AbbVie, Allergan (legacy), GlaxoSmithKline and Novartis. Direct peers are Jazz Pharmaceuticals, Lundbeck, Eli Lilly and Company and Takeda Pharmaceutical Company. CogniFit is listed as an emerging player.

Does Forest Laboratories have an API?

No public API is recorded for Forest Laboratories.

What industry is Forest Laboratories in?

Forest Laboratories's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BarchartExocrine Pancreatic Insufficiency Market: Expanding Revenue Landscape to 2034 – DelveInsight | First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest LaboratoriesDelveInsight released a market forecast report projecting the Exocrine Pancreatic Insufficiency market to reach approximately USD 2,500 million in 2021 with significant growth through 2034. The report highlights key industry players such as Abbott, First Wave BioPharma, and Anthera Pharmaceuticals, while noting specific developments like Anagram Therapeutics' collaboration with Epicured Inc. for enzyme replacement therapies.JD SupraFourth Circuit Reverses Dismissal of False Claims Act Case Against Drug Manufacturer, Applying Supreme Court’s Subjective Scienter StandardThe United States Court of Appeals for the Fourth Circuit reversed and remanded the dismissal of a qui tam False Claims Act lawsuit against Forest Laboratories, LLC (now Allergan Sales, LLC), marking the first application of the Supreme Court's subjective scienter standard from Schutte v. SuperValu Inc. The case centers on allegations that Forest engaged in rebate "stacking" practices and underpaid Medicaid by approximately $686.64 million over nearly a decade by failing to aggregate rebates when reporting its "Best Price" to CMS. The Fourth Circuit held that former employee relator Troy Sheldon adequately pled that Forest acted with reckless disregard, reversing the district court's dismissal.Data Insights MarketLearning Disabilities Treatment Growth Projections: Trends to WatchA market research report projects the global Learning Disabilities Treatment market to grow from an estimated $5 billion in 2022 at a Compound Annual Growth Rate (CAGR) of approximately 7% through 2033, driven by increased awareness, early diagnosis, technological advancements including AI-powered diagnostic tools and digital therapeutics, and rising demand for non-drug interventions. The report identifies key industry players including CogniFit, Eli Lilly & Company, Texthelp, Takeda Pharmaceutical, and Forest Laboratories, which have undertaken recent product launches, clinical trials, investments, and partnerships in the sector. North America and Europe are expected to dominate the market due to robust healthcare infrastructure, while the Asia Pacific region presents significant growth opportunities.PR NewswireMiller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust LitigationProposed settlements totaling over $56.4 million have been reached in the Namenda Indirect Purchaser Antitrust Litigation pending in the U.S. District Court for the Southern District of New York, with Brand Defendants (Actavis/Forest Laboratories and Merz) agreeing to pay $54.4 million and Generic Defendants (Teva, Dr. Reddy's, Wockhardt, and Amneal/Sun/Upsher-Smith) agreeing to pay $2.038 million. The lawsuit alleged that defendants engaged in a monopolization scheme to keep generic versions of the Alzheimer's disease drug Namenda XR and Namenda IR off the market, causing prices to be artificially inflated. Class members who purchased, paid for, or received reimbursement for Namenda or its generics between April 2010 and December 2017 may file claims by February 3, 2023, and a fairness hearing is scheduled for March 13, 2023.PR NewswireIchnos Sciences Adds Lawrence Olanoff, M.D., Ph.D., To Board Of DirectorsIchnos Sciences Inc. announced the appointment of Lawrence Olanoff, M.D., Ph.D., as an independent member of its Board of Directors. Dr. Olanoff brings over 30 years of pharmaceutical industry experience, including leadership roles at Forest Laboratories and Celsion Corporation, to guide the company's clinical-stage pipeline in oncology and autoimmune diseases.PR NewswireForest Resolves Antitrust Class Action Litigation with Direct Purchasers of NamendaForest Laboratories, a subsidiary of Allergan plc, has reached a $750 million settlement with a plaintiff class of direct purchasers of Namenda, resolving antitrust class action litigation pending in the U.S. District Court for the Southern District of New York. The settlement, which includes no admission of wrongdoing, was reached before the trial scheduled to begin in October 2019. Allergan will take a pre-tax GAAP charge of $750 million to its third quarter 2019 earnings.PR NewswireAllergan Announces Early Tender Results and Upsizing of Tender Offers by Certain SubsidiariesAllergan plc announced the early tender results for debt securities issued by its subsidiaries, including Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, LLC, and Allergan, Inc. The company subsequently upsized the maximum tender subcaps and the aggregate maximum tender cap to approximately $2.84 billion as the offers became fully subscribed. Final pricing is expected on May 24, 2017, with payments scheduled for May 30, 2017.PR NewswireAllergan Announces Pricing of Tender Offers by Certain SubsidiariesAllergan plc announced on May 24, 2017 the consideration payable for tender offers by its wholly-owned subsidiaries Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, LLC, and Allergan, Inc., to purchase various debt securities for cash. The tender offers cover multiple series of notes with principal amounts ranging from $650 million to $2.5 billion, subject to maximum tender caps and acceptance priority levels. The early settlement date is May 30, 2017, and the financing condition requires Allergan Funding SCS to issue senior notes expected to close on May 26, 2017.PR NewswireCorporate Whistleblower Now Urges a Doctor with Proof a Pharma Company is Illegally Using Speaker Fees to Get Physicians to Prescribe More Drugs to Call Them About Possible RewardsThe Corporate Whistleblower Center is urging physicians or pharmaceutical company insiders with evidence of drug companies bribing doctors through speaker fees, meals, or travel to come forward with information. The call follows a $38 million Department of Justice settlement with Forest Laboratories and Forest Pharmaceuticals to resolve allegations that the companies violated the Anti-Kickback Statute by providing payments and meals to physicians as inducements to prescribe their products. The whistleblower's share of the settlement totaled approximately $7.8 million, with the Center offering to help potential informants connect with leading whistleblower attorneys.PR NewswireMedical Affairs Reputations: Asthma/COPD (US)Reportlinker has published a market research report evaluating the reputations of medical affairs teams for seven leading asthma/COPD brands in the US, based on a survey of 100 pulmonologists and general practitioners. The report finds considerable variation in team perceptions, with US teams rated higher overall compared to EU5 markets, and identifies information fulfillment as the highest-scoring category while highlighting areas needing improvement. The study covers brands from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, Genentech/Novartis, GlaxoSmithKline, and Novartis, with one brand trailing competitors across all key attributes.